Indication
Stage IV Lip and Oral Cavity Squamous Cell Carcinoma
1 clinical trial
1 product
1 drug
Clinical trial
A Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaStatus: Completed, Estimated PCD: 2022-03-29
Drug
AtezolizumabProduct
Ficlatuzumab